Review Decision On sNDA For Actelion’s Tracleer Awaits Finalized REMS
This article was originally published in The Pink Sheet Daily
Executive Summary
An FDA “complete response” letter says the REMS the firm submitted in September 2008 must be finalized and approved before the agency can act on the expanded indication.
You may also be interested in...
PAH Market Heats Up: New Approvals For Actelion, United Therapeutics
With a Risk Evaluation and Mitigation Strategy for Tracleer now approved by FDA, Actelion can maximize the drug's selling potential across a broader range of pulmonary arterial hypertension patients before it faces generics in 2015
PAH Market Heats Up: New Approvals For Actelion, United Therapeutics
With a Risk Evaluation and Mitigation Strategy for Tracleer now approved by FDA, Actelion can maximize the drug's selling potential across a broader range of pulmonary arterial hypertension patients before it faces generics in 2015
PAH Market Snapshot: Actelion’s Tracleer Faces Stiffer U.S. Competition
United Therapeutics' recently approved pulmonary arterial hypertension drug Adcirca threatens to close in on the vast lead held by Actelion's Tracleer, though surpassing the market pioneer seems nearly impossible. Not to mention, the Swiss-based biotech has an ace up its sleeve with the expansive REVEAL patient registry